CFLAR and lung cancer: Upon observing the significant reduction of c-FLIP expression with the combination treatment with bortezomib and PCC, therefore, we sought to analyze the stability of c-FLIP protein in the combination treatment condition in H23 and H358 lung cancer cell lines.